These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 30931980)
41. Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients. Thill M; Fischer D; Kelling K; Hoellen F; Dittmer C; Hornemann A; Salehin D; Diedrich K; Friedrich M; Becker S J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):387-90. PubMed ID: 20304053 [TBL] [Abstract][Full Text] [Related]
42. Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Kochel TJ; Fulton AM Prostaglandins Other Lipid Mediat; 2015; 116-117():99-103. PubMed ID: 25433169 [TBL] [Abstract][Full Text] [Related]
43. miR-21 modulates prostaglandin signaling and promotes gastric tumorigenesis by targeting 15-PGDH. Li L; Wang X; Li W; Yang L; Liu R; Zeng R; Wu Y; Shou T Biochem Biophys Res Commun; 2018 Jan; 495(1):928-934. PubMed ID: 29101039 [TBL] [Abstract][Full Text] [Related]
44. 15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins. Lu D; Han C; Wu T J Biol Chem; 2013 Jul; 288(27):19484-502. PubMed ID: 23687300 [TBL] [Abstract][Full Text] [Related]
45. UV radiation inhibits 15-hydroxyprostaglandin dehydrogenase levels in human skin: evidence of transcriptional suppression. Judson BL; Miyaki A; Kekatpure VD; Du B; Gilleaudeau P; Sullivan-Whalen M; Mohebati A; Nair S; Boyle JO; Granstein RD; Subbaramaiah K; Krueger JG; Dannenberg AJ Cancer Prev Res (Phila); 2010 Sep; 3(9):1104-11. PubMed ID: 20643784 [TBL] [Abstract][Full Text] [Related]
46. Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer. Zhang B; Ma X; Li Z; Gao X; Wang F; Liu L; Shen G; Sang Y; Li M; Li Y; Zhao J; Wei Y J Cancer Res Clin Oncol; 2013 May; 139(5):797-807. PubMed ID: 23385883 [TBL] [Abstract][Full Text] [Related]
47. PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d. Huang L; Wen C; Yang X; Lou Q; Wang X; Che J; Chen J; Yang Z; Wu X; Huang M; Lan P; Wang L; Iwamoto A; Wang J; Liu H Cell Death Dis; 2018 Feb; 9(3):271. PubMed ID: 29449544 [TBL] [Abstract][Full Text] [Related]
48. Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors. Pham H; Chen M; Li A; King J; Angst E; Dawson DW; Park J; Reber HA; Hines OJ; Eibl G Pancreas; 2010 Apr; 39(3):332-9. PubMed ID: 19820419 [TBL] [Abstract][Full Text] [Related]
49. TRAF6-Mediated Inflammatory Cytokines Secretion in LPS-induced Colorectal Cancer Cells Is Regulated by miR-140. Zhu G; Lin C; Cheng Z; Wang Q; Hoffman RM; Singh SR; Huang Y; Zheng W; Yang S; Ye J Cancer Genomics Proteomics; 2020; 17(1):23-33. PubMed ID: 31882548 [TBL] [Abstract][Full Text] [Related]
50. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1β from activated macrophages leads to poor prognosis in pancreatic cancer. Arima K; Komohara Y; Bu L; Tsukamoto M; Itoyama R; Miyake K; Uchihara T; Ogata Y; Nakagawa S; Okabe H; Imai K; Hashimoto D; Chikamoto A; Yamashita YI; Baba H; Ishimoto T Cancer Sci; 2018 Feb; 109(2):462-470. PubMed ID: 29224225 [TBL] [Abstract][Full Text] [Related]
51. Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Wang J; Wang H; Liu A; Fang C; Hao J; Wang Z Oncotarget; 2015 Aug; 6(23):19456-68. PubMed ID: 26062441 [TBL] [Abstract][Full Text] [Related]
52. Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer. Kochel TJ; Reader JC; Ma X; Kundu N; Fulton AM Oncotarget; 2017 Jan; 8(4):6540-6554. PubMed ID: 28029661 [TBL] [Abstract][Full Text] [Related]
53. MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer. Lu G; Sun Y; An S; Xin S; Ren X; Zhang D; Wu P; Liao W; Ding Y; Liang L Exp Mol Pathol; 2015 Aug; 99(1):173-9. PubMed ID: 26103003 [TBL] [Abstract][Full Text] [Related]
54. Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene. Li M; Xie J; Cheng L; Chang B; Wang Y; Lan X; Zhang D; Yin Y; Cheng N Cancer Invest; 2008 Nov; 26(9):905-12. PubMed ID: 19034772 [TBL] [Abstract][Full Text] [Related]
55. Burn injury with infection alters prostaglandin E2 synthesis and metabolism. Hahn EL; Tai HH; He LK; Gamelli RL J Trauma; 1999 Dec; 47(6):1052-7; discussion 1057-9. PubMed ID: 10608532 [TBL] [Abstract][Full Text] [Related]
56. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Myung SJ; Rerko RM; Yan M; Platzer P; Guda K; Dotson A; Lawrence E; Dannenberg AJ; Lovgren AK; Luo G; Pretlow TP; Newman RA; Willis J; Dawson D; Markowitz SD Proc Natl Acad Sci U S A; 2006 Aug; 103(32):12098-102. PubMed ID: 16880406 [TBL] [Abstract][Full Text] [Related]
57. miR-133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway. Wang H; An H; Wang B; Liao Q; Li W; Jin X; Cui S; Zhang Y; Ding Y; Zhao L Eur J Cancer; 2013 Dec; 49(18):3924-35. PubMed ID: 23968734 [TBL] [Abstract][Full Text] [Related]
58. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Quidville V; Segond N; Lausson S; Frenkian M; Cohen R; Jullienne A Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):14-30. PubMed ID: 16997128 [TBL] [Abstract][Full Text] [Related]
59. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Wolf I; O'Kelly J; Rubinek T; Tong M; Nguyen A; Lin BT; Tai HH; Karlan BY; Koeffler HP Cancer Res; 2006 Aug; 66(15):7818-23. PubMed ID: 16885386 [TBL] [Abstract][Full Text] [Related]
60. Prostaglandin catabolic enzymes as tumor suppressors. Tai HH Cancer Metastasis Rev; 2011 Dec; 30(3-4):409-17. PubMed ID: 22020925 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]